Show simple item record

dc.contributor.authorSnowsill, T
dc.date.accessioned2023-01-24T12:48:40Z
dc.date.issued2023-01-23
dc.date.updated2023-01-24T09:19:28Z
dc.description.abstractDiagnostic tests are used to determine whether a disease or condition is present or absent in a patient, who will typically be suspected of having the disease or condition due to symptoms or clinical signs. Economic evaluations of diagnostic tests (e.g. cost-effectiveness analyses) can be used to determine whether a test produces sufficient benefit to justify its cost. Evidence on the benefits conferred by a test is often restricted to its accuracy, which means mathematical models are required to estimate the impact of a test on outcomes that matter to patients and health payers. It is important to realise the case for introducing a new test may not be restricted to its accuracy, but extend to factors such as time to diagnosis and acceptability for patients. These and other considerations may mean the common modelling approach, the decision tree, is inappropriate for underpinning an economic evaluation. There are no consensus guidelines on how economic evaluations of diagnostic tests should be conducted—this article attempts to explore the common challenges encountered in economic evaluations, suggests solutions to those challenges, and identifies some areas where further methodological work may be necessary.en_GB
dc.identifier.citationPublished online 23 January 2023en_GB
dc.identifier.doihttps://doi.org/10.1007/s40273-023-01241-2
dc.identifier.urihttp://hdl.handle.net/10871/132317
dc.identifierORCID: 0000-0001-7406-2819 (Snowsill, Tristan)
dc.language.isoenen_GB
dc.publisherSpringeren_GB
dc.rights.embargoreasonUnder embargo until 23 January 2024 in compliance with publisher policyen_GB
dc.rights© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023en_GB
dc.titleModelling the Cost-Effectiveness of Diagnostic Testsen_GB
dc.typeArticleen_GB
dc.date.available2023-01-24T12:48:40Z
dc.identifier.issn1170-7690
dc.descriptionThis is the author accepted manuscript. The final version is available from Springer via the DOI in this recorden_GB
dc.descriptionData availability: There are no data included in this article that are not in the public domain. The simulated example shown in Fig. 2 can be replicated by drawing (X1,X2) from a bivariate normal distribution with mean (0,0) and covariance matrix (10.40.41) , then simulating Z1∼N(X1,0.2),Z2∼N(X1,0.2) and Z3∼N(X2,0.2) , and finally simulating the test results as Y1=I(Z1>0.6) , Y2=I(Z2>0) and Y3=I(Z3>0.5) . The true disease status is given by I(X1+X2>1) .en_GB
dc.identifier.eissn1179-2027
dc.identifier.journalPharmacoEconomicsen_GB
dc.relation.ispartofPharmacoEconomics
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2023-01-08
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2023-01-23
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2023-01-24T10:37:50Z
refterms.versionFCDAM
refterms.dateFOA2024-01-23T00:00:00Z
refterms.panelAen_GB
refterms.dateFirstOnline2023-01-23


Files in this item

This item appears in the following Collection(s)

Show simple item record